CJC-1295 (No DAC) vs IGF-1 LR3
CJC-1295 (No DAC) and IGF-1 LR3 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 (No DAC) is ghrh(1-29) tetra-substituted analogue (dac-free), while IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1 — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution); their leading degradation routes differ (deamidation at asn/gln residues over long solution storage. for CJC-1295 (No DAC), denaturation and aggregation for IGF-1 LR3), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 (No DAC) — origin
CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
CJC-1295 (No DAC) research themes
Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.
The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.
Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
CJC-1295 (No DAC) handling
- Reach room temperature before opening.
- Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
- Aliquot and refrigerate; never re-freeze reconstituted solution.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Both third-party tested
Every Popular Peptides batch of CJC-1295 (No DAC) and IGF-1 LR3 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 (No DAC) reference
Related comparisons
CJC-1295 (No DAC) and IGF-1 LR3 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.